Glia maturation factor beta deficiency protects against diabetic osteoporosis by suppressing osteoclast hyperactivity
-
Published:2023-05-01
Issue:5
Volume:55
Page:898-909
-
ISSN:2092-6413
-
Container-title:Experimental & Molecular Medicine
-
language:en
-
Short-container-title:Exp Mol Med
Author:
Shi Si, Gu Huijie, Xu Jinyuan, Sun Wan, Liu Caiyin, Zhu Tong, Wang Juan, Gao Furong, Zhang Jieping, Ou QingjianORCID, Jin Caixia, Xu Jingying, Chen Hao, Li Jiao, Xu Guotong, Tian Haibin, Lu Lixia
Abstract
AbstractExcessive osteoclast activation, which depends on dramatic changes in actin dynamics, causes osteoporosis (OP). The molecular mechanism of osteoclast activation in OP related to type 1 diabetes (T1D) remains unclear. Glia maturation factor beta (GMFB) is considered a growth and differentiation factor for both glia and neurons. Here, we demonstrated that Gmfb deficiency effectively ameliorated the phenotype of T1D-OP in rats by inhibiting osteoclast hyperactivity. In vitro assays showed that GMFB participated in osteoclast activation rather than proliferation. Gmfb deficiency did not affect osteoclast sealing zone (SZ) formation but effectively decreased the SZ area by decreasing actin depolymerization. When GMFB was overexpressed in Gmfb-deficient osteoclasts, the size of the SZ area was enlarged in a dose-dependent manner. Moreover, decreased actin depolymerization led to a decrease in nuclear G-actin, which activated MKL1/SRF-dependent gene transcription. We found that pro-osteoclastogenic factors (Mmp9 and Mmp14) were downregulated, while anti-osteoclastogenic factors (Cftr and Fhl2) were upregulated in Gmfb KO osteoclasts. A GMFB inhibitor, DS-30, targeting the binding site of GMFB and Arp2/3, was obtained. Biocore analysis revealed a high affinity between DS-30 and GMFB in a dose-dependent manner. As expected, DS-30 strongly suppressed osteoclast hyperactivity in vivo and in vitro. In conclusion, our work identified a new therapeutic strategy for T1D-OP treatment. The discovery of GMFB inhibitors will contribute to translational research on T1D-OP.
Funder
the Fundamental Research Funds for the Central Universities, China Natural Science Foundation of Shanghai National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Clinical Biochemistry,Molecular Biology,Molecular Medicine,Biochemistry
Reference54 articles.
1. Miller, R. G., Secrest, A. M., Sharma, R. K., Songer, T. J. & Orchard, T. J. Improvements in the life expectancy of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications study cohort. Diabetes 61, 2987–2992 (2012). 2. McCabe, L. R. Understanding the pathology and mechanisms of type I diabetic bone loss. J. Cell. Biochem. 102, 1343–1357 (2007). 3. Jeddi, S., Yousefzadeh, N., Kashfi, K. & Ghasemi, A. Role of nitric oxide in type 1 diabetes-induced osteoporosis. Biochem. Pharmacol. 197, 114888 (2022). 4. Kemink, S. A., Hermus, A. R., Swinkels, L. M., Lutterman, J. A. & Smals, A. G. Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J. Endocrinol. Invest. 23, 295–303 (2000). 5. Kasahara, T. et al. Malfunction of bone marrow-derived osteoclasts and the delay of bone fracture healing in diabetic mice. Bone 47, 617–625 (2010).
|
|